News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

FDA Staff Unconvinced By Johnson & Johnson (JNJ)'s Latest Xarelto Application


1/14/2014 7:20:33 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

The U.S. Food and Drug Administration appears skeptical that data submitted by Johnson & Johnson proves its anticoagulant Xarelto is effective in reducing the risk of further heart problems in patients who have suffered a heart attack. The review was posted on the FDA's website on Tuesday, two days ahead of a meeting of outside experts who will discuss the drug, also known as rivaroxaban, and recommend whether it should be approved.

Help employers find you! Check out all the jobs and post your resume.

Read at Reuters
Read at Seeking Alpha


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES